HSD17B13 inhibitor
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- BOEHRINGER INGELHEIM INT GMBH
- Filing Date
- 2023-06-06
- Publication Date
- 2026-06-15
AI Technical Summary
Current treatments for non-alcoholic steatohepatitis (NASH) and related liver diseases lack effective inhibitors targeting HSD17B13, a key enzyme implicated in these conditions, necessitating the development of potent and selective HSD17B13 inhibitors to manage lipid biosynthesis and disease progression.
Development of heteroaryl-substituted 2,6-difluorophenol compounds that act as selective HSD17B13 inhibitors, capable of modulating lipid biosynthesis and potentially treating conditions like NASH and metabolic disorders, with the compounds existing in various tautomeric forms and being administered in combination with additional therapeutic agents.
The compounds effectively inhibit HSD17B13, offering therapeutic benefits in treating non-alcoholic steatohepatitis and metabolic disorders, with flexible dosing regimens and formulations for optimal patient outcomes.
Smart Images

Figure 2023237504000001 
Figure 2023237504000002 
Figure 2023237504000003